Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 43 (ONC43) Topics Include:  , and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Full Course:
Full Course Price:
Short Course:
Short Course Price:
Available in Audio format.

Course Topics

Highlights from the 5th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure

Assess the need for reflex HER2 testing in equivocal cases on the basis of clinical, pathologic, and genotypic features; Analyze the rationale for PD-L1 inhibitor therapy in patients with triple-negative breast cancer; Predict patients with atypical HER2 genotypes who are most likely to benefit from HER2-targeted therapy; Summarize updated guidelines for management of estrogenreceptor-positive, triple-negative, and HER2-positive breast cancer; Select patients with early-stage breast cancer who are most likely to benefit from extended endocrine therapy.

Highlights from the Scripps MD Anderson 2019 Oncology Update

Select the optimal therapeutic regimen for patients with EGFR-mutated lung cancer based on tumor mutational burden; Identify factors associated with high rate of response to programmed cell death protein 1 (PD-1) inhibitor therapy in patients with lung cancer; Elaborate on new options for treatment of small cell lung cancer; Recognize common patterns of recurrence in patients with melanoma; Provide patients with effective options for treatment of melanoma based on their therapeutic history and whether brain metastases are present.


Highlights from the 6th Annual USC Multi-Disciplinary Breast Cancer Symposium

Evaluate the relationship between genomic risk and response to endocrine therapy or chemotherapy; Assess the effect of patient age and nodal status on prediction of benefit from endocrine therapy or chemotherapy; Describe the relationship between clinical or pathologic features and genomic risk for breast cancer; Compare the efficacy of radiation therapy and lymph node dissection based on recent updates of clinical trials; Estimate age-related risk for breast cancer in individuals with germline mutations commonly associated with cancer.

Prostate Cancer Update / Outcomes of Advanced Radiation Techniques for Head and Neck Cancer

Summarize recent changes in management of prostate cancer; Select appropriate therapies for metastatic castrationsensitive prostate cancer based on volume of disease and location of metastases; Assess the benefits and disadvantages of chemotherapy and androgen receptor-targeted therapies for patients with prostate cancer; Develop strategies for radiation planning that optimize the therapeutic ratio in patients with head and neck cancer; Estimate risk for late-onset adverse events following conventional and intensity-modulated radiation therapy for patients with head and neck cancer.

Highlights from the 4th Annual David Stroud Adolescent and Young Adult Oncology Symposium

Identify factors that influence the importance of achieving negative surgical margins in patients with soft tissue sarcoma; Recognize common subtypes of soft tissue sarcoma in adolescent and young adult patients; Implement multidisciplinary approaches and standard-ofcare strategies for treatment of common subtypes of soft tissue sarcoma in adolescent and young adult patients; Elaborate on findings of recent studies of novel targeted therapies for soft tissue sarcoma; Explain how DNA and RNA sequencing can identify targets for treatment of soft tissue sarcoma.

Early Detection of Pancreatic Cancer /End-of-Life Care

Explain the rationale for current recommendations for screening of pancreatic cancer; Recognize the characteristics and malignant potential of common types of pancreatic cysts; Identify which patients with intraductal papillary mucinous neoplasms (IPMNs) should undergo surgical resection; Summarize postsurgical and oncologic outcomes of patients with IPMNs and pancreatic ductal carcinoma; Develop approaches for palliative care of patients with colorectal cancer.

Pancreatic Cancer/Colorectal Cancer

Recognize challenges and limitations associated with standard methods for analysis of pancreatic cysts and biliary strictures; Identify common genomic alterations in ancreatic cysts associated with progression to high-grade dysplasia or cancer; Use genomic analysis to distinguish between aggressive and indolent pancreatic neuroendocrine tumors; Choose appropriate candidates for molecular testing to diagnose malignant biliary strictures; Develop plans for surveillance of colorectal cancer based on personal history, family history, and patient preferences for testing.

Updates on Hematologic Malignancies and Radiation Oncology

Summarize outcomes and safety of targeted therapies for chronic lymphocytic leukemia; Select appropriate management strategies for smoldering and frank multiple myeloma; Assess benefits and drawbacks of autologous and allogeneic transplantation for peripheral T cell lymphoma; Review recent trials of radiation therapy for solid malignancies; Evaluate the safety of concurrent checkpoint inhibitor therapy with chemoradiotherapy in locally advanced, unresectable lung cancer.


Highlights from Melanoma 2020: 30th Annual Cutaneous Malignancy Update

Recognize the contributions of pioneers in the diagnosis and treatment of melanoma; Identify characteristics of the various subtypes of melanoma; Elaborate on the use of molecular testing in the diagnosis of melanoma; Diagnose subtypes of melanoma using histology and molecular testing; Assess prognosis in patients with melanoma.

Highlights from Scripps Melanoma 2020: 30th Annual Cutaneous Malignancy Update: Diagnosis and Treatment

Recognize the value of early diagnosis of melanoma; 2. Compare and contrast current methods for diagnosis of melanoma; Explain how computer-based applications may be used in the future to perform diagnostic evaluations for melanoma; Summarize the efficacy and safety of immunotherapies and targeted therapies for adjuvant treatment of melanoma; Select a systemic therapy for adjuvant treatment of melanoma on the basis of patient comorbidities, histologic and molecular characteristics of the tumor, and anatomic location of disease.


Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  SurgeryFamily PracticeInternal MedicineObesity and Nutrition.

If you have taken the current Oncology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Oncology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.